NOVARTIS

The FDA approves Ruxoprubart for Phase II efficacy trial in IgAN patients, a selective inhibitor of the alternative complement pathway, potentially treating multiple disorders without affecting the classical pathway.

The article discusses the importance of enabling JavaScript for optimal app performance.

The global psoriasis drug market is valued at US$ 14.08 billion in 2024, projected to grow at a CAGR of 6.9% to US$ 27.57 billion by 2034. Factors like smoking, alcohol, and cold temperatures increase psoriasis risk, driving market growth, especially in cold climates like the U.S. Key players include Amgen, Eli Lilly, and Novartis, focusing on strategic partnerships and product innovations. Corticosteroids are widely used for psoriasis treatment, prompting increased production by manufacturers.

Olema Oncology announces a clinical trial collaboration with Novartis and a $250 million private placement, supporting Phase 3 OPERA-02 trial in ER+/HER2- metastatic breast cancer and ongoing clinical studies.

The global Combination Antibody Therapy market is projected to grow from $178.1B in 2023 to $443B by 2030, driven by cancer prevalence, immunotherapy advancements, and personalized medicine. The report by ResearchAndMarkets.com offers insights into market trends, drivers, and forecasts.

The idiopathic pulmonary fibrosis market is projected to grow from $3.89 billion in 2023 to $5.24 billion in 2028 at a CAGR of 6.2%, driven by factors like an aging population, limited treatment options, and advancements in diagnostic techniques. Key trends include product innovation and the rise of targeted therapies.

The drug discovery technologies market is projected to grow from $66.08 billion in 2023 to $108.31 billion by 2028, driven by advancements in genomic research, AI, and precision medicine. Key trends include AI integration, 3D cell culture, and blockchain for data security. Market drivers include the rising prevalence of chronic diseases and the development of advanced technologies by companies like Google.

Black Friday sale offers 20% off The Scenarionist Premium Annual Plan. Deep Tech Briefing #40 covers AI policy, startup funding, eVTOL sector challenges, AI standards, space tech advancements, protein AI innovation, energy scaling issues, and quantum computing progress.

DelveInsight's 'Graft versus host disease Pipeline Insight 2024' covers 60+ companies and 65+ pipeline drugs, including clinical and nonclinical stage products, with a focus on therapeutics assessment by product type, stage, route of administration, and molecule type. Key companies and promising therapies in development are highlighted.